JP2013527170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013527170A5 JP2013527170A5 JP2013508570A JP2013508570A JP2013527170A5 JP 2013527170 A5 JP2013527170 A5 JP 2013527170A5 JP 2013508570 A JP2013508570 A JP 2013508570A JP 2013508570 A JP2013508570 A JP 2013508570A JP 2013527170 A5 JP2013527170 A5 JP 2013527170A5
- Authority
- JP
- Japan
- Prior art keywords
- ylcarbamoyl
- benzoic acid
- chloro
- difluorobiphenyl
- difluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2- (3-chlorobiphenyl-4-ylcarbamoyl) benzoic acid Chemical compound 0.000 claims description 113
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 67
- 150000001875 compounds Chemical class 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 5
- SBHJMNICVOXTQZ-UHFFFAOYSA-N 2-[[4-(3-ethylphenyl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound CCC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 SBHJMNICVOXTQZ-UHFFFAOYSA-N 0.000 claims description 3
- TWQHHHPXDZGCIG-UHFFFAOYSA-N ClC1=C(C=C(C=C1)OC)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)Cl.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=C(C=C1)OC)OC Chemical compound ClC1=C(C=C(C=C1)OC)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)Cl.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=C(C=C1)OC)OC TWQHHHPXDZGCIG-UHFFFAOYSA-N 0.000 claims description 3
- FICLAEURQAAHTA-UHFFFAOYSA-N FC1=C(C(=CC(=C1)C=1C=C2C(=CNC2=CC1)C)F)NC(=O)C1=C(C(=O)O)C=CC=C1.FC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=C(C=C1)F)OC Chemical compound FC1=C(C(=CC(=C1)C=1C=C2C(=CNC2=CC1)C)F)NC(=O)C1=C(C(=O)O)C=CC=C1.FC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=C(C=C1)F)OC FICLAEURQAAHTA-UHFFFAOYSA-N 0.000 claims description 3
- BMHUUYIRKGWQOG-UHFFFAOYSA-N 2-[[2,6-difluoro-4-(2-fluoro-5-methoxyphenyl)phenyl]carbamoyl]benzoic acid Chemical compound COC1=CC=C(F)C(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 BMHUUYIRKGWQOG-UHFFFAOYSA-N 0.000 claims description 2
- QKVOWFUJEINWNQ-UHFFFAOYSA-N 2-[[2,6-difluoro-4-(3-methyl-2h-indazol-5-yl)phenyl]carbamoyl]benzoic acid Chemical compound C1=C2C(C)=NNC2=CC=C1C(C=C1F)=CC(F)=C1NC(=O)C1=CC=CC=C1C(O)=O QKVOWFUJEINWNQ-UHFFFAOYSA-N 0.000 claims description 2
- OIIQWCVDOBWRMJ-UHFFFAOYSA-N 2-[[2,6-difluoro-4-(3-propan-2-yloxyphenyl)phenyl]carbamoyl]benzoic acid Chemical compound CC(C)OC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 OIIQWCVDOBWRMJ-UHFFFAOYSA-N 0.000 claims description 2
- UFDYYDSVVQSNDS-UHFFFAOYSA-N 2-[[2,6-difluoro-4-[3-(trifluoromethoxy)phenyl]phenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C(OC(F)(F)F)C=CC=2)C=C1F UFDYYDSVVQSNDS-UHFFFAOYSA-N 0.000 claims description 2
- IQAORFMYZPKQBX-UHFFFAOYSA-N 2-[[4-(1,3-benzodioxol-5-yl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C3OCOC3=CC=2)C=C1F IQAORFMYZPKQBX-UHFFFAOYSA-N 0.000 claims description 2
- NCVIXOCOLVIPLS-UHFFFAOYSA-N 2-[[4-(3-cyclopropyloxyphenyl)-2-fluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=2C=C(OC3CC3)C=CC=2)C=C1F NCVIXOCOLVIPLS-UHFFFAOYSA-N 0.000 claims description 2
- LEHLVDDUGIBISB-UHFFFAOYSA-N 2-[[4-(3-ethoxyphenyl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound CCOC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 LEHLVDDUGIBISB-UHFFFAOYSA-N 0.000 claims description 2
- JCCCPFBYVRGUPS-UHFFFAOYSA-N 2-[[4-(3-ethylphenyl)phenyl]carbamoyl]benzoic acid Chemical compound CCC1=CC=CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3)C(O)=O)=CC=2)=C1 JCCCPFBYVRGUPS-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims 29
- 235000010233 benzoic acid Nutrition 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 150000002431 hydrogen Chemical group 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000006414 CCl Chemical group ClC* 0.000 claims 3
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 3
- 102100033461 Interleukin-17A Human genes 0.000 claims 3
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 2
- 101710088194 Dehydrogenase Proteins 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 150000008065 acid anhydrides Chemical class 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- UFIVEPVSAGBUSI-UHFFFAOYSA-N dihydroorotic acid Chemical compound OC(=O)C1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- YNVYQKPNYNUJGZ-UHFFFAOYSA-N 2-[[2,6-difluoro-4-(2-fluorophenyl)phenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C(=CC=CC=2)F)C=C1F YNVYQKPNYNUJGZ-UHFFFAOYSA-N 0.000 claims 1
- HNRIJIAFLCALMB-UHFFFAOYSA-N 2-[[2-chloro-4-(3-cyclopentyloxyphenyl)-6-fluorophenyl]carbamoyl]benzoic acid 2-[[4-[3-(difluoromethoxy)phenyl]-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound FC(OC=1C=C(C=CC1)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F)F.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OC1CCCC1 HNRIJIAFLCALMB-UHFFFAOYSA-N 0.000 claims 1
- LHQYZGSHIDHMFV-UHFFFAOYSA-N 2-[[2-chloro-4-[3-(difluoromethoxy)phenyl]-6-fluorophenyl]carbamoyl]benzoic acid 2-[[4-(2-chloro-5-methoxyphenyl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound ClC1=C(C=C(C=C1)OC)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OC(F)F LHQYZGSHIDHMFV-UHFFFAOYSA-N 0.000 claims 1
- OSZLNJXHFPFJIP-UHFFFAOYSA-N 2-[[2-chloro-4-[3-(difluoromethoxy)phenyl]-6-fluorophenyl]carbamoyl]benzoic acid 2-[[4-[3-(difluoromethoxy)phenyl]-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OC(F)F.FC(OC=1C=C(C=CC1)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F)F OSZLNJXHFPFJIP-UHFFFAOYSA-N 0.000 claims 1
- KJOYEPSKYFDKLM-UHFFFAOYSA-N 2-[[2-chloro-6-fluoro-4-[3-(trifluoromethoxy)phenyl]phenyl]carbamoyl]benzoic acid 2-[(2,6-difluoro-4-phenylmethoxyphenyl)carbamoyl]benzoic acid Chemical compound C(C1=CC=CC=C1)OC1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OC(F)(F)F KJOYEPSKYFDKLM-UHFFFAOYSA-N 0.000 claims 1
- GOVXKUCVZUROAN-UHFFFAOYSA-N 3-ethyl-1h-indole Chemical compound C1=CC=C2C(CC)=CNC2=C1 GOVXKUCVZUROAN-UHFFFAOYSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- BONSAMLNNLHYSV-UHFFFAOYSA-N C1(CCCC1)OC=1C=C(C=CC1)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F.C(C1=CC=CC=C1)OC1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F Chemical compound C1(CCCC1)OC=1C=C(C=CC1)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F.C(C1=CC=CC=C1)OC1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F BONSAMLNNLHYSV-UHFFFAOYSA-N 0.000 claims 1
- OONOSCXDNGTQLB-UHFFFAOYSA-N CN1N=C(C2=CC(=CC=C12)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F)C.ClC1=C(C(=CC(=C1)C=1C=CC2=C(CCO2)C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1 Chemical compound CN1N=C(C2=CC(=CC=C12)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F)C.ClC1=C(C(=CC(=C1)C=1C=CC2=C(CCO2)C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1 OONOSCXDNGTQLB-UHFFFAOYSA-N 0.000 claims 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 1
- PSCJGWHQAIUEET-UHFFFAOYSA-N ClC1=C(C(=CC(=C1)C=1C=C2C(=CNC2=CC1)CC)F)NC(=O)C1=C(C(=O)O)C=CC=C1.FC1=C(C(=CC(=C1)C=1C=C2C(=CNC2=CC1)CCC)F)NC(=O)C1=C(C(=O)O)C=CC=C1 Chemical compound ClC1=C(C(=CC(=C1)C=1C=C2C(=CNC2=CC1)CC)F)NC(=O)C1=C(C(=O)O)C=CC=C1.FC1=C(C(=CC(=C1)C=1C=C2C(=CNC2=CC1)CCC)F)NC(=O)C1=C(C(=O)O)C=CC=C1 PSCJGWHQAIUEET-UHFFFAOYSA-N 0.000 claims 1
- QCIBXDQMEHXQID-UHFFFAOYSA-N ClC1=CC(=C(C(=O)O)C=C1Cl)C(NC1=C(C=C(C=C1F)C1=C(C=CC=C1)Cl)F)=O.C(CCC)OC=1C=C(C=CC1)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)Cl Chemical compound ClC1=CC(=C(C(=O)O)C=C1Cl)C(NC1=C(C=C(C=C1F)C1=C(C=CC=C1)Cl)F)=O.C(CCC)OC=1C=C(C=CC1)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)Cl QCIBXDQMEHXQID-UHFFFAOYSA-N 0.000 claims 1
- STKHSDVCMQFGCR-UHFFFAOYSA-N ClC1=CC(=C(C(=O)O)C=C1Cl)C(NC1=C(C=C(C=C1F)C1=CC(=CC=C1)OC)F)=O.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OCC Chemical compound ClC1=CC(=C(C(=O)O)C=C1Cl)C(NC1=C(C=C(C=C1F)C1=CC(=CC=C1)OC)F)=O.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OCC STKHSDVCMQFGCR-UHFFFAOYSA-N 0.000 claims 1
- TWQYMBDLIGHTGB-UHFFFAOYSA-N ClC=1C=C(C=C(C1)OC)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F.CN1N=C(C2=CC(=CC=C12)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F)C Chemical compound ClC=1C=C(C=C(C1)OC)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F.CN1N=C(C2=CC(=CC=C12)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F)C TWQYMBDLIGHTGB-UHFFFAOYSA-N 0.000 claims 1
- OLSRZNOBBAVTEO-UHFFFAOYSA-N ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)Cl)C1=CC(=CC=C1)OC.ClC1=CC(=C(C(=O)O)C=C1Cl)C(NC1=C(C=C(C=C1F)C1=CC(=CC=C1)OCC)F)=O Chemical compound ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)Cl)C1=CC(=CC=C1)OC.ClC1=CC(=C(C(=O)O)C=C1Cl)C(NC1=C(C=C(C=C1F)C1=CC(=CC=C1)OCC)F)=O OLSRZNOBBAVTEO-UHFFFAOYSA-N 0.000 claims 1
- FFARWXFJMDUFJF-UHFFFAOYSA-N ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)Cl)C1=CC(=CC=C1)OCC.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=C(C=CC=C1)F.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OCCC Chemical compound ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)Cl)C1=CC(=CC=C1)OCC.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=C(C=CC=C1)F.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OCCC FFARWXFJMDUFJF-UHFFFAOYSA-N 0.000 claims 1
- ZZMKIJZRUVUEDS-UHFFFAOYSA-N ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)CC.FC1=C(C(=CC(=C1)C=1C=C2C(=NNC2=CC1)C)F)NC(=O)C1=C(C(=O)O)C=CC=C1 Chemical compound ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)CC.FC1=C(C(=CC(=C1)C=1C=C2C(=NNC2=CC1)C)F)NC(=O)C1=C(C(=O)O)C=CC=C1 ZZMKIJZRUVUEDS-UHFFFAOYSA-N 0.000 claims 1
- DOLNZTDHFVFPEN-UHFFFAOYSA-N ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OC1CCCC1.C1(CCCC1)OC=1C=C(C=CC1)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F Chemical compound ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OC1CCCC1.C1(CCCC1)OC=1C=C(C=CC1)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F DOLNZTDHFVFPEN-UHFFFAOYSA-N 0.000 claims 1
- XNFJLRFEUNAXKE-UHFFFAOYSA-N ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OCC(F)(F)F.ClC1=C(C(=CC(=C1)C1=CC2=C(OCCO2)C=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1 Chemical compound ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OCC(F)(F)F.ClC1=C(C(=CC(=C1)C1=CC2=C(OCCO2)C=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1 XNFJLRFEUNAXKE-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- WDLMAJPTRMDXEC-UHFFFAOYSA-N FC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC(=C1)OC)F.ClC1=C(C=C(C=C1)OC)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F Chemical compound FC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC(=C1)OC)F.ClC1=C(C=C(C=C1)OC)C1=CC(=C(C(=C1)F)NC(=O)C1=C(C(=O)O)C=CC=C1)F WDLMAJPTRMDXEC-UHFFFAOYSA-N 0.000 claims 1
- GBQQWWSFCYHBSR-UHFFFAOYSA-N FC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OCCC.FC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OC(C)C.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)Cl)C1=C(C=CC=C1)F Chemical compound FC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OCCC.FC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)OC(C)C.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)Cl)C1=C(C=CC=C1)F GBQQWWSFCYHBSR-UHFFFAOYSA-N 0.000 claims 1
- 208000028387 Felty syndrome Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- ZQFGTOMIBBWQHM-UHFFFAOYSA-N O1CCC2=C1C=CC(=C2)C2=CC(=C(C(=C2)F)NC(=O)C2=C(C(=O)O)C=CC=C2)F.ClC=2C=C(C=C(C2NC(=O)C2=C(C(=O)O)C=CC=C2)F)C2=CC(=CC(=C2)OC)Cl Chemical compound O1CCC2=C1C=CC(=C2)C2=CC(=C(C(=C2)F)NC(=O)C2=C(C(=O)O)C=CC=C2)F.ClC=2C=C(C=C(C2NC(=O)C2=C(C(=O)O)C=CC=C2)F)C2=CC(=CC(=C2)OC)Cl ZQFGTOMIBBWQHM-UHFFFAOYSA-N 0.000 claims 1
- RIFXBODASCKXOD-UHFFFAOYSA-N O1COC2=C1C=CC(=C2)C2=CC(=C(C(=C2)F)NC(=O)C2=C(C(=O)O)C=CC=C2)F.FC=2C=C(C=C(C2NC(=O)C2=C(C(=O)O)C=CC=C2)F)C2=CC(=CC(=C2)OC)F Chemical compound O1COC2=C1C=CC(=C2)C2=CC(=C(C(=C2)F)NC(=O)C2=C(C(=O)O)C=CC=C2)F.FC=2C=C(C=C(C2NC(=O)C2=C(C(=O)O)C=CC=C2)F)C2=CC(=CC(=C2)OC)F RIFXBODASCKXOD-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 241000876474 Sapho Species 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 241000219094 Vitaceae Species 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- 208000027993 eye symptom Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 235000021021 grapes Nutrition 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000019764 polyarticular juvenile idiopathic arthritis Diseases 0.000 claims 1
- 244000000040 protozoan parasite Species 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000009169 relapsing polychondritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- GZZPPTDQQAARBH-UHFFFAOYSA-N 3,6-dichloro-2-[[4-(3-ethoxyphenyl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound CCOC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=C(Cl)C=CC=3Cl)C(O)=O)=C(F)C=2)=C1 GZZPPTDQQAARBH-UHFFFAOYSA-N 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- YFVKZWQSSLLXMA-UHFFFAOYSA-N 2-[(2,6-difluoro-4-phenylmethoxyphenyl)carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC(C(=C1)F)=C(F)C=C1OCC1=CC=CC=C1 YFVKZWQSSLLXMA-UHFFFAOYSA-N 0.000 description 1
- SLUINPGXGFUMLL-UHFFFAOYSA-N 2-[(4-phenylphenyl)carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=2C=CC=CC=2)C=C1 SLUINPGXGFUMLL-UHFFFAOYSA-N 0.000 description 1
- IKFDPISOISOHEP-UHFFFAOYSA-N 2-[[2,6-dichloro-4-(2-chlorophenyl)phenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(Cl)C=C(C=2C(=CC=CC=2)Cl)C=C1Cl IKFDPISOISOHEP-UHFFFAOYSA-N 0.000 description 1
- KNNRIBJQPJXFFX-UHFFFAOYSA-N 2-[[2,6-dichloro-4-(2-fluorophenyl)phenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(Cl)C=C(C=2C(=CC=CC=2)F)C=C1Cl KNNRIBJQPJXFFX-UHFFFAOYSA-N 0.000 description 1
- IJUKXGUNCZMVLH-UHFFFAOYSA-N 2-[[2,6-dichloro-4-(3-ethoxyphenyl)phenyl]carbamoyl]benzoic acid Chemical compound CCOC1=CC=CC(C=2C=C(Cl)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(Cl)C=2)=C1 IJUKXGUNCZMVLH-UHFFFAOYSA-N 0.000 description 1
- GTRGTKFEBSDHPH-UHFFFAOYSA-N 2-[[2,6-difluoro-4-(3-fluoro-5-methoxyphenyl)phenyl]carbamoyl]benzoic acid Chemical compound COC1=CC(F)=CC(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 GTRGTKFEBSDHPH-UHFFFAOYSA-N 0.000 description 1
- TYGSPWSEFVXANX-UHFFFAOYSA-N 2-[[2,6-difluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]benzoic acid Chemical compound COC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 TYGSPWSEFVXANX-UHFFFAOYSA-N 0.000 description 1
- PJCAGTGNNCRWEX-UHFFFAOYSA-N 2-[[2,6-difluoro-4-(3-propyl-1h-indol-5-yl)phenyl]carbamoyl]benzoic acid Chemical compound C1=C2C(CCC)=CNC2=CC=C1C(C=C1F)=CC(F)=C1NC(=O)C1=CC=CC=C1C(O)=O PJCAGTGNNCRWEX-UHFFFAOYSA-N 0.000 description 1
- CWNTYKVDWUDIBU-UHFFFAOYSA-N 2-[[2,6-difluoro-4-[3-(2,2,2-trifluoroethoxy)phenyl]phenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C(OCC(F)(F)F)C=CC=2)C=C1F CWNTYKVDWUDIBU-UHFFFAOYSA-N 0.000 description 1
- AVYIYFIFGKBARA-UHFFFAOYSA-N 2-[[2,6-difluoro-4-[3-(2-methylpropoxy)phenyl]phenyl]carbamoyl]benzoic acid Chemical compound CC(C)COC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 AVYIYFIFGKBARA-UHFFFAOYSA-N 0.000 description 1
- DYEAOLLYQXNTCM-UHFFFAOYSA-N 2-[[2-chloro-4-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-fluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C3OCCOC3=CC=2)C=C1Cl DYEAOLLYQXNTCM-UHFFFAOYSA-N 0.000 description 1
- XDXWFGRSHUBLLV-UHFFFAOYSA-N 2-[[2-chloro-4-(2,3-dihydro-1-benzofuran-5-yl)-6-fluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C3CCOC3=CC=2)C=C1Cl XDXWFGRSHUBLLV-UHFFFAOYSA-N 0.000 description 1
- GCIYOVFCDPEOTG-UHFFFAOYSA-N 2-[[2-chloro-4-(3-chloro-5-methoxyphenyl)-6-fluorophenyl]carbamoyl]benzoic acid Chemical compound COC1=CC(Cl)=CC(C=2C=C(Cl)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 GCIYOVFCDPEOTG-UHFFFAOYSA-N 0.000 description 1
- NTBFJLVAHFWXKA-UHFFFAOYSA-N 2-[[2-chloro-4-(3-cyclopentyloxyphenyl)-6-fluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C(OC3CCCC3)C=CC=2)C=C1Cl NTBFJLVAHFWXKA-UHFFFAOYSA-N 0.000 description 1
- BQHCLVHJZRBPFT-UHFFFAOYSA-N 2-[[2-chloro-4-(3-ethoxyphenyl)-6-fluorophenyl]carbamoyl]-6-fluorobenzoic acid Chemical compound CCOC1=CC=CC(C=2C=C(Cl)C(NC(=O)C=3C(=C(F)C=CC=3)C(O)=O)=C(F)C=2)=C1 BQHCLVHJZRBPFT-UHFFFAOYSA-N 0.000 description 1
- ZDWLTOJLPBNWPK-UHFFFAOYSA-N 2-[[2-chloro-4-(3-ethyl-1h-indol-5-yl)-6-fluorophenyl]carbamoyl]benzoic acid Chemical compound C1=C2C(CC)=CNC2=CC=C1C(C=C1Cl)=CC(F)=C1NC(=O)C1=CC=CC=C1C(O)=O ZDWLTOJLPBNWPK-UHFFFAOYSA-N 0.000 description 1
- KBWLFBSENBYQCF-UHFFFAOYSA-N 2-[[2-chloro-4-[3-(difluoromethoxy)phenyl]-6-fluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C(OC(F)F)C=CC=2)C=C1Cl KBWLFBSENBYQCF-UHFFFAOYSA-N 0.000 description 1
- ZTSFFKNGRVGEHJ-UHFFFAOYSA-N 2-[[2-chloro-6-fluoro-4-(2-fluorophenyl)phenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C(=CC=CC=2)F)C=C1Cl ZTSFFKNGRVGEHJ-UHFFFAOYSA-N 0.000 description 1
- YSWXHRWWAYMRPG-UHFFFAOYSA-N 2-[[2-chloro-6-fluoro-4-[3-(2,2,2-trifluoroethoxy)phenyl]phenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C(OCC(F)(F)F)C=CC=2)C=C1Cl YSWXHRWWAYMRPG-UHFFFAOYSA-N 0.000 description 1
- QCRDWJHKDYYGHG-UHFFFAOYSA-N 2-[[2-chloro-6-fluoro-4-[3-(2-methylpropoxy)phenyl]phenyl]carbamoyl]benzoic acid Chemical compound CC(C)COC1=CC=CC(C=2C=C(Cl)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 QCRDWJHKDYYGHG-UHFFFAOYSA-N 0.000 description 1
- BSUKYFDLRFQKFS-UHFFFAOYSA-N 2-[[2-fluoro-4-[3-(trifluoromethoxy)phenyl]phenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=2C=C(OC(F)(F)F)C=CC=2)C=C1F BSUKYFDLRFQKFS-UHFFFAOYSA-N 0.000 description 1
- VTNGWACCYAMIJW-UHFFFAOYSA-N 2-[[4-(1,3-benzodioxol-5-yl)-2-chloro-6-fluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C3OCOC3=CC=2)C=C1Cl VTNGWACCYAMIJW-UHFFFAOYSA-N 0.000 description 1
- PTZJIOCGGDKZJN-UHFFFAOYSA-N 2-[[4-(1,3-dimethylindazol-5-yl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound C1=C2C(C)=NN(C)C2=CC=C1C(C=C1F)=CC(F)=C1NC(=O)C1=CC=CC=C1C(O)=O PTZJIOCGGDKZJN-UHFFFAOYSA-N 0.000 description 1
- ACLUFPXTZILUAZ-UHFFFAOYSA-N 2-[[4-(2,3-dihydro-1-benzofuran-5-yl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C3CCOC3=CC=2)C=C1F ACLUFPXTZILUAZ-UHFFFAOYSA-N 0.000 description 1
- NNKTXHGWDZWQOR-UHFFFAOYSA-N 2-[[4-(2-chloro-5-methoxyphenyl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound COC1=CC=C(Cl)C(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 NNKTXHGWDZWQOR-UHFFFAOYSA-N 0.000 description 1
- SNNXUOXMESGPIP-UHFFFAOYSA-N 2-[[4-(2-chlorophenyl)phenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=2C(=CC=CC=2)Cl)C=C1 SNNXUOXMESGPIP-UHFFFAOYSA-N 0.000 description 1
- YTJOLOOTXFVTIR-UHFFFAOYSA-N 2-[[4-(2-fluorophenyl)-2-(trifluoromethoxy)phenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=2C(=CC=CC=2)F)C=C1OC(F)(F)F YTJOLOOTXFVTIR-UHFFFAOYSA-N 0.000 description 1
- XZUFHSXCNNNGFS-UHFFFAOYSA-N 2-[[4-(3-butoxyphenyl)-2,3,5,6-tetrafluorophenyl]carbamoyl]benzoic acid Chemical compound CCCCOC1=CC=CC(C=2C(=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2F)F)=C1 XZUFHSXCNNNGFS-UHFFFAOYSA-N 0.000 description 1
- YETZVOVKXKTYRX-UHFFFAOYSA-N 2-[[4-(3-butoxyphenyl)-2-chloro-6-fluorophenyl]carbamoyl]benzoic acid Chemical compound CCCCOC1=CC=CC(C=2C=C(Cl)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 YETZVOVKXKTYRX-UHFFFAOYSA-N 0.000 description 1
- HSPDNPLPHOSOCK-UHFFFAOYSA-N 2-[[4-(3-butoxyphenyl)-2-fluorophenyl]carbamoyl]benzoic acid Chemical compound CCCCOC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=CC=2)=C1 HSPDNPLPHOSOCK-UHFFFAOYSA-N 0.000 description 1
- QNWTUTURBRIWIB-UHFFFAOYSA-N 2-[[4-(3-butoxyphenyl)-3,5-difluorophenyl]carbamoyl]benzoic acid Chemical compound CCCCOC1=CC=CC(C=2C(=CC(NC(=O)C=3C(=CC=CC=3)C(O)=O)=CC=2F)F)=C1 QNWTUTURBRIWIB-UHFFFAOYSA-N 0.000 description 1
- GJSKQMIEYFEJFM-UHFFFAOYSA-N 2-[[4-(3-butoxyphenyl)-3-fluorophenyl]carbamoyl]benzoic acid Chemical compound CCCCOC1=CC=CC(C=2C(=CC(NC(=O)C=3C(=CC=CC=3)C(O)=O)=CC=2)F)=C1 GJSKQMIEYFEJFM-UHFFFAOYSA-N 0.000 description 1
- ORXUOSZHTQLOEW-UHFFFAOYSA-N 2-[[4-(3-butoxyphenyl)phenyl]carbamoyl]benzoic acid Chemical compound CCCCOC1=CC=CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3)C(O)=O)=CC=2)=C1 ORXUOSZHTQLOEW-UHFFFAOYSA-N 0.000 description 1
- HGGLHTOONNUODM-UHFFFAOYSA-N 2-[[4-(3-chloro-5-methoxyphenyl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound COC1=CC(Cl)=CC(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 HGGLHTOONNUODM-UHFFFAOYSA-N 0.000 description 1
- DILCTJVAXXHVEQ-UHFFFAOYSA-N 2-[[4-(3-cyclopentyloxyphenyl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C(OC3CCCC3)C=CC=2)C=C1F DILCTJVAXXHVEQ-UHFFFAOYSA-N 0.000 description 1
- HEKROFSZDURFOY-UHFFFAOYSA-N 2-[[4-(3-cyclopropyloxyphenyl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C(OC3CC3)C=CC=2)C=C1F HEKROFSZDURFOY-UHFFFAOYSA-N 0.000 description 1
- VGWXBYVVYUFEAK-UHFFFAOYSA-N 2-[[4-(3-cyclopropyloxyphenyl)phenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=2C=C(OC3CC3)C=CC=2)C=C1 VGWXBYVVYUFEAK-UHFFFAOYSA-N 0.000 description 1
- XYWRBLKSTYCZFW-UHFFFAOYSA-N 2-[[4-(3-ethoxyphenyl)-2,6-difluorophenyl]carbamoyl]pyridine-3-carboxylic acid Chemical compound CCOC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=CC=CN=3)C(O)=O)=C(F)C=2)=C1 XYWRBLKSTYCZFW-UHFFFAOYSA-N 0.000 description 1
- CUQZZVZCIHFYFI-UHFFFAOYSA-N 2-[[4-(3-ethoxyphenyl)-2-fluorophenyl]carbamoyl]benzoic acid Chemical compound CCOC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=CC=2)=C1 CUQZZVZCIHFYFI-UHFFFAOYSA-N 0.000 description 1
- LTXCDSKEUZPTDY-UHFFFAOYSA-N 2-[[4-(3-ethyl-1h-indol-5-yl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound C1=C2C(CC)=CNC2=CC=C1C(C=C1F)=CC(F)=C1NC(=O)C1=CC=CC=C1C(O)=O LTXCDSKEUZPTDY-UHFFFAOYSA-N 0.000 description 1
- WBRKNEXQCSETIJ-UHFFFAOYSA-N 2-[[4-(3-ethylsulfanylphenyl)-2,3,5,6-tetrafluorophenyl]carbamoyl]benzoic acid Chemical compound CCSC1=CC=CC(C=2C(=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2F)F)=C1 WBRKNEXQCSETIJ-UHFFFAOYSA-N 0.000 description 1
- IDNACNXVOZNRFL-UHFFFAOYSA-N 2-[[4-(3-ethylsulfanylphenyl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound CCSC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 IDNACNXVOZNRFL-UHFFFAOYSA-N 0.000 description 1
- VBZPOQLUFOCIHB-UHFFFAOYSA-N 2-[[4-(3-ethylsulfanylphenyl)-3,5-difluorophenyl]carbamoyl]benzoic acid Chemical compound CCSC1=CC=CC(C=2C(=CC(NC(=O)C=3C(=CC=CC=3)C(O)=O)=CC=2F)F)=C1 VBZPOQLUFOCIHB-UHFFFAOYSA-N 0.000 description 1
- IAOJIDHQNRCUHM-UHFFFAOYSA-N 2-[[4-(3-ethylsulfanylphenyl)-3-fluorophenyl]carbamoyl]benzoic acid Chemical compound CCSC1=CC=CC(C=2C(=CC(NC(=O)C=3C(=CC=CC=3)C(O)=O)=CC=2)F)=C1 IAOJIDHQNRCUHM-UHFFFAOYSA-N 0.000 description 1
- SSFOVPXAWTZCJA-UHFFFAOYSA-N 2-[[4-(3-methoxyphenyl)phenyl]carbamoyl]benzoic acid Chemical compound COC1=CC=CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3)C(O)=O)=CC=2)=C1 SSFOVPXAWTZCJA-UHFFFAOYSA-N 0.000 description 1
- XLTNDVPERNSXGZ-UHFFFAOYSA-N 2-[[4-(3-propoxyphenyl)phenyl]carbamoyl]benzoic acid Chemical compound CCCOC1=CC=CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3)C(O)=O)=CC=2)=C1 XLTNDVPERNSXGZ-UHFFFAOYSA-N 0.000 description 1
- KGFGNYNKXZXPJC-UHFFFAOYSA-N 2-[[4-(4-chloro-3-methoxyphenyl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound C1=C(Cl)C(OC)=CC(C=2C=C(F)C(NC(=O)C=3C(=CC=CC=3)C(O)=O)=C(F)C=2)=C1 KGFGNYNKXZXPJC-UHFFFAOYSA-N 0.000 description 1
- DRPSYLIQUFPILF-UHFFFAOYSA-N 2-[[4-[3-(difluoromethoxy)phenyl]-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=C(F)C=C(C=2C=C(OC(F)F)C=CC=2)C=C1F DRPSYLIQUFPILF-UHFFFAOYSA-N 0.000 description 1
- GGYDCRTUIKTHPA-UHFFFAOYSA-N 2-[[4-[3-(trifluoromethoxy)phenyl]phenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=2C=C(OC(F)(F)F)C=CC=2)C=C1 GGYDCRTUIKTHPA-UHFFFAOYSA-N 0.000 description 1
- LTQPZEASZGKDNP-UHFFFAOYSA-N 3-[[2,6-difluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]pyrazine-2-carboxylic acid Chemical compound COC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=NC=CN=3)C(O)=O)=C(F)C=2)=C1 LTQPZEASZGKDNP-UHFFFAOYSA-N 0.000 description 1
- MIPBXZOEJIHSHP-UHFFFAOYSA-N 3-[[2,6-difluoro-4-(3-phenylmethoxyphenyl)phenyl]carbamoyl]pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CN=C1C(=O)NC1=C(F)C=C(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)C=C1F MIPBXZOEJIHSHP-UHFFFAOYSA-N 0.000 description 1
- IYZUGVZRPZQNQB-UHFFFAOYSA-N 3-[[2-chloro-4-(3-ethoxyphenyl)-6-fluorophenyl]carbamoyl]pyrazine-2-carboxylic acid Chemical compound CCOC1=CC=CC(C=2C=C(Cl)C(NC(=O)C=3C(=NC=CN=3)C(O)=O)=C(F)C=2)=C1 IYZUGVZRPZQNQB-UHFFFAOYSA-N 0.000 description 1
- MPOLCFAWJCFTJW-UHFFFAOYSA-N 3-[[4-(3-ethoxyphenyl)-2,6-difluorophenyl]carbamoyl]pyrazine-2-carboxylic acid Chemical compound CCOC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=NC=CN=3)C(O)=O)=C(F)C=2)=C1 MPOLCFAWJCFTJW-UHFFFAOYSA-N 0.000 description 1
- OWZVJAVYACMDSX-UHFFFAOYSA-N 4,5-dichloro-2-[[2,6-difluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]benzoic acid Chemical compound COC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=CC(Cl)=C(Cl)C=3)C(O)=O)=C(F)C=2)=C1 OWZVJAVYACMDSX-UHFFFAOYSA-N 0.000 description 1
- GGJPSQSAMUBJSM-UHFFFAOYSA-N 4,5-dichloro-2-[[2-chloro-4-(2-chlorophenyl)-6-fluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC(Cl)=C(Cl)C=C1C(=O)NC1=C(F)C=C(C=2C(=CC=CC=2)Cl)C=C1Cl GGJPSQSAMUBJSM-UHFFFAOYSA-N 0.000 description 1
- MTNKYQOAEFWVRZ-UHFFFAOYSA-N 4,5-dichloro-2-[[4-(2-chlorophenyl)-2,6-difluorophenyl]carbamoyl]benzoic acid Chemical compound OC(=O)C1=CC(Cl)=C(Cl)C=C1C(=O)NC1=C(F)C=C(C=2C(=CC=CC=2)Cl)C=C1F MTNKYQOAEFWVRZ-UHFFFAOYSA-N 0.000 description 1
- HEGLMCPFDADCAQ-UHFFFAOYSA-N 4,7-dichloro-2-benzofuran-1,3-dione Chemical compound ClC1=CC=C(Cl)C2=C1C(=O)OC2=O HEGLMCPFDADCAQ-UHFFFAOYSA-N 0.000 description 1
- ISQIBEIMLQYAFJ-UHFFFAOYSA-N 4-[[4-(3-ethoxyphenyl)-2,6-difluorophenyl]carbamoyl]pyridine-3-carboxylic acid Chemical compound CCOC1=CC=CC(C=2C=C(F)C(NC(=O)C=3C(=CN=CC=3)C(O)=O)=C(F)C=2)=C1 ISQIBEIMLQYAFJ-UHFFFAOYSA-N 0.000 description 1
- 0 C*c1cc(F)c(C)c(F)c1 Chemical compound C*c1cc(F)c(C)c(F)c1 0.000 description 1
- DMXBTUVHCAMVQL-UHFFFAOYSA-N Cc1cc(Cl)c(C)c(Cl)c1 Chemical compound Cc1cc(Cl)c(C)c(Cl)c1 DMXBTUVHCAMVQL-UHFFFAOYSA-N 0.000 description 1
- UYASIFBSPDHHBL-UHFFFAOYSA-N ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=C(C(=CC=C1)OCC)F.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)CC Chemical compound ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=C(C(=CC=C1)OCC)F.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC=C1)CC UYASIFBSPDHHBL-UHFFFAOYSA-N 0.000 description 1
- BKIPWGCGJUCHRX-UHFFFAOYSA-N ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=C(C=CC(=C1)OC)F.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=C(C=C1)Cl)OC Chemical compound ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=C(C=CC(=C1)OC)F.ClC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=C(C=C1)Cl)OC BKIPWGCGJUCHRX-UHFFFAOYSA-N 0.000 description 1
- KELDMSXOQUNJOA-UHFFFAOYSA-N FC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC(=C1)OC)F.FC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=C(C=C1)OC)OC Chemical compound FC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=CC(=C1)OC)F.FC=1C=C(C=C(C1NC(=O)C1=C(C(=O)O)C=CC=C1)F)C1=CC(=C(C=C1)OC)OC KELDMSXOQUNJOA-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1265CH2010 | 2010-05-06 | ||
| IN1265/CHE/2010 | 2010-05-06 | ||
| PCT/IB2011/000959 WO2011138665A1 (en) | 2010-05-06 | 2011-05-06 | Novel immunomodulator and anti inflammatory compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013527170A JP2013527170A (ja) | 2013-06-27 |
| JP2013527170A5 true JP2013527170A5 (https=) | 2014-07-10 |
| JP6207393B2 JP6207393B2 (ja) | 2017-10-04 |
Family
ID=44359772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508570A Expired - Fee Related JP6207393B2 (ja) | 2010-05-06 | 2011-05-06 | 新規免疫調節剤および抗炎症化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8686048B2 (https=) |
| EP (1) | EP2566847B8 (https=) |
| JP (1) | JP6207393B2 (https=) |
| KR (1) | KR101865310B1 (https=) |
| CN (1) | CN103097353B (https=) |
| AU (1) | AU2011249546C1 (https=) |
| CA (1) | CA2798056C (https=) |
| CY (1) | CY1121357T1 (https=) |
| DK (1) | DK2566847T3 (https=) |
| EA (1) | EA024702B8 (https=) |
| ES (1) | ES2709975T3 (https=) |
| HR (1) | HRP20190195T1 (https=) |
| HU (1) | HUE041220T2 (https=) |
| IL (1) | IL222882A (https=) |
| LT (1) | LT2566847T (https=) |
| NZ (1) | NZ603935A (https=) |
| PL (1) | PL2566847T3 (https=) |
| PT (1) | PT2566847T (https=) |
| RS (1) | RS58363B1 (https=) |
| SI (1) | SI2566847T1 (https=) |
| SM (1) | SMT201900077T1 (https=) |
| TR (1) | TR201901114T4 (https=) |
| WO (1) | WO2011138665A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012109329A2 (en) | 2011-02-08 | 2012-08-16 | Children's Medical Center Corporation | Methods for treatment of melanoma |
| BR112014005935A2 (pt) | 2011-09-16 | 2017-03-28 | Fovea Pharmaceuticals | derivados de anilina, sua preparação e sua aplicação terapêutica |
| ES2551427T3 (es) | 2012-02-06 | 2015-11-19 | William L. Pridgen | Combinación de famciclovir y celecoxib para síndromes somáticos funcionales |
| CN103961349A (zh) * | 2013-02-06 | 2014-08-06 | 西南大学 | 抗风湿类药物来氟米特(Leflunomide)抑制神经母细胞瘤生长 |
| PL3139914T3 (pl) * | 2014-05-08 | 2023-11-27 | Kiora Pharmaceuticals Gmbh | Związki stosowane w leczeniu chorób i schorzeń okulistycznych |
| TWI691486B (zh) * | 2016-01-29 | 2020-04-21 | 日商東麗股份有限公司 | 環狀胺衍生物及其醫藥用途 |
| CN114921391B (zh) | 2016-10-27 | 2024-01-02 | 拜耳股份有限公司 | 4,5-环状1,2,4-三唑酮 |
| US11555009B2 (en) * | 2017-03-02 | 2023-01-17 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | 2-(substituted benzene matrix) aromatic formate FTO inhibitor, preparation method therefor, and applications thereof |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2019018562A1 (en) | 2017-07-19 | 2019-01-24 | Ideaya Biosciences, Inc. | AMIDO COMPOUND AS MODULATORS OF AHR |
| EP3498694A1 (en) * | 2017-12-12 | 2019-06-19 | Medibiofarma, S.L. | New benzamide derivatives as ppar-gamma modulators |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| WO2019163945A1 (ja) * | 2018-02-22 | 2019-08-29 | 学校法人東海大学 | Ｉｌ－１７ａ活性阻害剤およびその用途 |
| ES2972099T3 (es) | 2018-03-09 | 2024-06-11 | Kiora Pharmaceuticals Gmbh | Formulación oftálmica |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN110950807B (zh) * | 2018-09-26 | 2023-03-03 | 中国科学院上海药物研究所 | 联芳基类化合物、其制备方法、药物组合物及其应用 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2020219423A1 (en) * | 2019-04-25 | 2020-10-29 | Clear Creek Bio, Inc. | Combination therapies including inhibitors of dihydroorotate dehydrogenase |
| AU2020370110A1 (en) * | 2019-10-21 | 2022-05-26 | Rhizen Pharmaceuticals Ag | Compositions comprising a DHODH inhibitor for the treatment of acute myeloid leukemia |
| CN111559977B (zh) * | 2020-06-04 | 2021-06-22 | 广州市朝利良生物科技有限公司 | 一类小分子化合物及其在制备抗肿瘤转移药物中应用 |
| WO2022167402A1 (en) | 2021-02-02 | 2022-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of therapy comprising administering a therapeutically effective combination comprising a dhodh inhibitor and an idh inhibitor |
| WO2025215126A1 (en) | 2024-04-12 | 2025-10-16 | Immunic Ag | Synthesis of vidofludimus and its calcium salt |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2474893A (en) | 1949-07-05 | Phthalamidic acid compounds of | ||
| US247489A (en) * | 1881-09-27 | Machine for painting barrel-heads | ||
| DE887501C (de) | 1950-11-11 | 1953-08-24 | Schering Ag | Verfahren zur Herstellung von Abkoemmlingen von Aminodiphenylen |
| US2710871A (en) * | 1951-12-05 | 1955-06-14 | Eastman Kodak Co | Preparation of 5-pyrazolone diamides |
| US3914418A (en) * | 1971-09-02 | 1975-10-21 | Merck & Co Inc | Methods of controlling liver fluke infections |
| DE2705974A1 (de) * | 1977-02-12 | 1978-08-17 | Agfa Gevaert Ag | Verfahren zur herstellung farbphotographischer bilder unter verwendung neuartiger weisskupplersubstanzen |
| JPS6039215B2 (ja) * | 1978-08-09 | 1985-09-05 | 三菱製紙株式会社 | 着色されたハロゲン化銀写真感光材料 |
| US4710515A (en) * | 1987-03-17 | 1987-12-01 | Riker Laboratories, Inc. | Substituted biphenyl derivatives |
| JPH0240382A (ja) * | 1988-07-28 | 1990-02-09 | Nippon Soda Co Ltd | ピリダジノン誘導体及びその製法 |
| US5976848A (en) | 1990-08-03 | 1999-11-02 | Dow Agrosciences Llc | Method of identifying potential fungicides using dihydroorotate dehydrogenase inhibition assay |
| JP3053490B2 (ja) * | 1991-02-25 | 2000-06-19 | 杏林製薬株式会社 | チアゾリジン−２，４−ジオン誘導体とその塩及び製造法 |
| JPH0844114A (ja) * | 1994-07-29 | 1996-02-16 | Mitsubishi Chem Corp | 静電荷像現像用帯電制御剤、並びにそれを用いたトナー及び電荷付与剤 |
| GB9520092D0 (en) | 1995-10-02 | 1995-12-06 | Hoechst Roussel Ltd | Chemical compounds |
| DE19610955A1 (de) | 1996-03-20 | 1997-09-25 | Hoechst Ag | Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid |
| TW515786B (en) * | 1997-11-25 | 2003-01-01 | Nihon Nohyaku Co Ltd | Phthalic acid diamide derivatives, agricultural and horticultural insecticides, and a method for application of the insecticides |
| AU2108099A (en) | 1998-01-30 | 1999-08-16 | Procept, Inc. | Immunosuppressive agents |
| AR015514A1 (es) | 1998-02-10 | 2001-05-02 | Novartis Ag | Compuesto de amida, proceso para su preparacion y composicion farmaceutica que lo contiene |
| GB9804343D0 (en) | 1998-02-27 | 1998-04-22 | Univ Cardiff | Chemical compounds |
| JP2003510352A (ja) | 1999-10-01 | 2003-03-18 | インスティチュート オブ モレキュラー アンド セル バイオロジー | ウイルス媒介性疾病の治療用化合物 |
| US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| DE10010425A1 (de) * | 2000-03-03 | 2001-09-06 | Bayer Ag | Substituierte 5-Methyldihydropyridazinone und ihre Verwendung |
| DE10010426A1 (de) * | 2000-03-03 | 2001-09-06 | Bayer Ag | Verwendung von 6-[4-Aminopheny]-dihydropyridazinonen |
| AU2002228317A1 (en) * | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Benz-1,3-azole derivatives and their uses as heparanase inhibitors |
| EP1381356B1 (en) | 2001-04-05 | 2008-05-28 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| EP1389612A4 (en) * | 2001-04-26 | 2004-06-02 | Nihon Nohyaku Co Ltd | PHTHALAMIDE DERIVATIVES, INSECTICIDES FOR USE IN AGRICULTURE AND GARDENING AND METHOD FOR THE USE THEREOF |
| SE0102384D0 (sv) * | 2001-07-03 | 2001-07-03 | Pharmacia Ab | New compounds |
| MXPA04000224A (es) * | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
| JPWO2003030905A1 (ja) | 2001-10-01 | 2005-01-20 | 塩野義製薬株式会社 | ジヒドロオロテートデヒドロゲナーゼ阻害剤 |
| EP1515940A2 (en) | 2002-05-17 | 2005-03-23 | Lica Pharmaceuticals A/S | Aminoalkoxy-functional chalcones |
| FR2841346B1 (fr) * | 2002-06-19 | 2004-11-05 | Eastman Kodak Co | Procede de developpement d'un produit photographique a haut contraste contenant un agent de nucleation de type polyhydrazide |
| CN1747949A (zh) * | 2002-12-20 | 2006-03-15 | 法马西亚公司 | 无环吡唑化合物 |
| US7071355B2 (en) | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| US7247736B2 (en) | 2002-12-23 | 2007-07-24 | 4Sc Ag | Method of identifying inhibitors of DHODH |
| MXPA05006890A (es) | 2002-12-23 | 2006-04-07 | 4Sc Ag | Compuestos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos. |
| EP1581478A1 (en) | 2002-12-23 | 2005-10-05 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| AU2003302305A1 (en) * | 2002-12-31 | 2004-07-22 | Sachin S Bhagwat | Benzoquinolizine-2-carboxylic acid-containing compositions |
| WO2005028467A1 (en) * | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
| US20050146263A1 (en) * | 2003-09-25 | 2005-07-07 | Kelly Stephen M. | Lighting elements, devices and methods |
| EP1537858A1 (en) * | 2003-12-04 | 2005-06-08 | Vectron Therapeutics AG | Drug delivery vehicles and uses thereof |
| SE0400234D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New compounds, methods for their preparation and use thereof |
| JPWO2005108370A1 (ja) * | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| EP1763346A4 (en) | 2004-05-21 | 2009-03-04 | Uab Research Foundation | COMPOSITIONS AND METHODS RELATED TO PYRIMIDINE SYNTHESIS |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| TW200616613A (en) | 2004-10-05 | 2006-06-01 | Shionogi & Co | Biaryl derivatives |
| CA2584655A1 (en) | 2004-10-19 | 2006-04-27 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| JPWO2006051937A1 (ja) | 2004-11-15 | 2008-05-29 | 塩野義製薬株式会社 | ヘテロ５員環誘導体 |
| BRPI0612028A2 (pt) * | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| US20070099970A1 (en) * | 2005-08-19 | 2007-05-03 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain |
| EP2298308B1 (en) * | 2005-11-14 | 2013-01-16 | University Of Southern California | Integrin-binding small molecules |
| MX2008010187A (es) * | 2006-02-10 | 2008-10-31 | Summit Corp Plc | Tratamiento de distrofia muscular de duchenne. |
| US20080027079A1 (en) | 2006-06-22 | 2008-01-31 | Board Of Regents, University Of Texas System | Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity |
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| JP5349332B2 (ja) | 2007-02-06 | 2013-11-20 | チェルシー・セラピューティクス，インコーポレイテッド | 新規化合物、その調製方法、およびその使用 |
| CN101298442B (zh) * | 2007-04-30 | 2010-07-07 | 中国科学院化学研究所 | 基于2-(2'-羟基苯基)苯并唑的酰胺类化合物及其制法和用途 |
| JP2010535708A (ja) * | 2007-08-03 | 2010-11-25 | ビオマリン アイジーエー リミテッド | デュシェンヌ型筋ジストロフィーの治療のための薬物併用 |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| US7960400B2 (en) | 2007-08-27 | 2011-06-14 | Duquesne University Of The Holy Ghost | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof |
| US7982035B2 (en) | 2007-08-27 | 2011-07-19 | Duquesne University Of The Holy Spirit | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof |
| US9216983B2 (en) | 2007-12-21 | 2015-12-22 | Board Of Regents, University Of Texas System | Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity |
| GB0808029D0 (en) | 2008-05-01 | 2008-06-11 | F2G Ltd | Antifungal target |
| WO2009137081A2 (en) | 2008-05-07 | 2009-11-12 | Massachusetts Institute Of Technology | Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase |
| EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| JP2010030970A (ja) * | 2008-07-31 | 2010-02-12 | Bayer Cropscience Ag | 殺虫性ベンゼンジカルボキサミド誘導体 |
| CN102271674A (zh) * | 2008-11-07 | 2011-12-07 | 4Sc股份公司 | 用于治疗自身免疫病的包含dhodh抑制剂和氨甲喋呤的联合治疗 |
| US8859620B2 (en) | 2009-08-31 | 2014-10-14 | University Of Notre Dame Du Lac | Phthalanilate compounds and methods of use |
-
2011
- 2011-05-05 US US13/101,921 patent/US8686048B2/en active Active
- 2011-05-06 KR KR1020127031799A patent/KR101865310B1/ko not_active Expired - Fee Related
- 2011-05-06 AU AU2011249546A patent/AU2011249546C1/en not_active Ceased
- 2011-05-06 DK DK11738472.7T patent/DK2566847T3/en active
- 2011-05-06 PT PT11738472T patent/PT2566847T/pt unknown
- 2011-05-06 LT LTEP11738472.7T patent/LT2566847T/lt unknown
- 2011-05-06 HR HRP20190195TT patent/HRP20190195T1/hr unknown
- 2011-05-06 EP EP11738472.7A patent/EP2566847B8/en active Active
- 2011-05-06 WO PCT/IB2011/000959 patent/WO2011138665A1/en not_active Ceased
- 2011-05-06 ES ES11738472T patent/ES2709975T3/es active Active
- 2011-05-06 HU HUE11738472A patent/HUE041220T2/hu unknown
- 2011-05-06 CN CN201180028730.7A patent/CN103097353B/zh not_active Expired - Fee Related
- 2011-05-06 TR TR2019/01114T patent/TR201901114T4/tr unknown
- 2011-05-06 NZ NZ603935A patent/NZ603935A/en not_active IP Right Cessation
- 2011-05-06 EA EA201291099A patent/EA024702B8/ru unknown
- 2011-05-06 SI SI201131663T patent/SI2566847T1/sl unknown
- 2011-05-06 PL PL11738472T patent/PL2566847T3/pl unknown
- 2011-05-06 RS RS20190155A patent/RS58363B1/sr unknown
- 2011-05-06 JP JP2013508570A patent/JP6207393B2/ja not_active Expired - Fee Related
- 2011-05-06 SM SM20190077T patent/SMT201900077T1/it unknown
- 2011-05-06 CA CA2798056A patent/CA2798056C/en active Active
-
2012
- 2012-11-05 IL IL222882A patent/IL222882A/en active IP Right Grant
-
2014
- 2014-02-04 US US14/172,707 patent/US9758474B2/en active Active
-
2019
- 2019-01-30 CY CY20191100126T patent/CY1121357T1/el unknown